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Remarkable progress has been made on developing an in vivo assay using the X-linked phosphatidylinositol glycan class A gene (Pig-a) as an endogenous reporter of mutagenicity (1) . The Pig-a gene codes for the catalytic subunit of an N-acetylglucosamine transferase that is involved in the synthesis of glycosylphosphatidylinositol (GPI). Mutations in the Pig-a gene can abolish GPI synthesis, resulting in a deficiency of the GPI anchored protein markers (e.g., CD59 or CD24) expressed on the cell surface. Unlike the other genes required for GPI synthesis (e.g., Pig-b and Pig-c), the Pig-a gene is located on the X chromosome, so that a single mutation can result in an altered cellular phenotype. In addition, since the Pig-a gene is highly conserved in mammals, mutation analysis using the Pig-a gene (Pig-a assay) is anticipated to be a useful trans-species tool for evaluating the in vivo mutagenicity of chemicals.
Based on the biological principles described above, the Pig-a assay employs flow cytometry to discriminate GPI-deficient cells (Pig-a mutant phenotype) from wildtype cells by using fluorescently conjugated antibodies against one or more GPI-anchored protein markers. At present, the assay has been conducted most often using peripheral red blood cells (RBCs) from rodents (especially rats). Research worldwide is now focusing on the next step in assay development: multi-laboratory trials to confirm the robustness and transferability of the assay and to establish its performance for detecting in vivo mutagens (2, 3) . Related to these issues, the International Workshop on Genotoxicity Testing has organized a workgroup on the Pig-a assay to discuss progress on developing the assay and how the assay can be used for the genotoxicity risk assessment of chemicals (4) .
Collaborative work on the Pig-a assay has been conducted in Japan as part of the project entitled`Study on the development of an integrated system of toxicology assays that can evaluate multiple endpoints,' supported by the Japan Health Sciences Foundation, Grants No. KHB1006 and KHB1209. The Pig-a assay can be performed with microliter volumes of blood so that the integration of the assay into repeated dose toxicology studies is feasible. The goal of the collaborative studies was to develop a protocol that can acquire in vivo genetic toxicity data in a manner consistent with the principles of the 3Rs (Replacement, Reduction, and Refinement of animals in research). To this end, five laboratories have evaluated the transferability of the rat Pig-a assay in RBCs (RBC Pig-a assay) and reticulocytes (PIGRET assay) using an antibody to erythroid marker HIS49. The first trial was successful in demonstating that the Pig-a assay protocol was technically transferable and that assay results were reproducible among the participant laboratories (3). Of special note was the finding that the PIGRET assay may detect the in vivo mutagenicity of chemicals earlier than the RBC Pig-a assay. This outcome encouraged the participating laboratories to perform further studies.
This Special Issue is organized by participants of the above collaborative study. The first article by Miura reviews the history of the Pig-a assay and its prospects for research applications in the field of genetic toxicology. Articles by four of five participating laboratories report on studies conducted to evaluate the mutagenicty of several reference chemicals using both the rat RBC Pig-a assay and the PIGRET assay and employing single-dose and 28-day repeated-dose treatments. . The short communication by Horibata et al. reports on the feasibility of integrating the RBC Pig-a and PIGRET assays into a transgenic gene mutation study using N-ethyl-Nnitrosourea-treated gpt delta rats. The researchers con-ducting these studies express the hope that their enthusiasm for developing the Pig-a assay carries over to readers of these reports and encourages their interest in supporting and participating in these emerging efforts.
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